[CLSTR]
< Back to situations

[ORGANIZATION]

Mounjaro

Featured in 39 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [BR] [PY] [FR]

Brazil ANVISA expands product safety enforcement

31 clusters · 227 sources · last updated

Latest: Brazil combats illegal weight-loss drug market as Anvisa fast-tracks generics

Since May 2026, Brazil’s National Health Surveillance Agency (ANVISA) has intensified enforcement of sanitary rules for pharmaceuticals, cosmetics, and consumer goods. Early actions included suspending batches of statins

[ACTIVE] [HEALTH] [US] [BR] [GB]

GLP-1 drugs: clinical trends, safety, and market shifts

246 clusters · 894 sources · last updated

Latest: Medical experts propose management system for GLP-1 obesity drugs

Since mid-2026, the expansion of GLP-1 agents for obesity has been accompanied by intensified safety monitoring and evolving clinical data. Research suggests secondary benefits, including a 21% lower risk of fragility fr

[ACTIVE] [HEALTH] [US] [DE] [GB]

Eli Lilly retatrutide development and black market issues

8 clusters · 26 sources · last updated

Latest: Retatrutid shows significant weight loss in Phase 3 trials

In early August 2026, Eli Lilly announced that its experimental obesity treatment retatrutide achieved substantial weight-loss outcomes in two phase-3 trials. Participants lost up to 22.6% of body weight over 80 weeks in

[ACTIVE] [HEALTH] [AR] [ES] [MX]

Health alerts over unregulated pharmaceutical products

4 clusters · 23 sources · last updated

Latest: ANMAT issues alert over illegal weight loss injections

Health authorities in the Americas continue to issue warnings regarding the sale of unregulated supplements and unauthorized pharmaceutical products containing undeclared active ingredients. In the United States and Mex

[ACTIVE] [HEALTH] [BR] [MX] [TR]

Body image and GLP-1 medication trends in Brazil

5 clusters · 90 sources · last updated

Latest: GLP-1 weight loss medications spark clinical debate among health professionals

Health experts and regulatory bodies in Brazil are intensifying warnings regarding the use of GLP-1 receptor agonists, such as semaglutide and tirzepatide, for weight loss. While effective for obesity, a systematic revie

[QUIET] [BUSINESS] [US]

Eli Lilly acquisition of Merida Biosciences

2 clusters · 19 sources · last updated

Latest: Eli Lilly to acquire Merida Biosciences for up to $2.875 billion

Eli Lilly and Company has entered into a definitive agreement to acquire Merida Biosciences, a biotechnology firm based in Cambridge, Massachusetts, for a total value of approximately $2.88 billion. The deal structure co

[QUIET] [HEALTH] [DK] [US]

Biological mechanisms of obesity and weight regain

2 clusters · 3 sources · last updated

Latest: Science identifies biological drivers behind obesity and weight regain

Scientific research is increasingly characterizing obesity as a chronic disease driven by biological defense mechanisms rather than willpower. Studies indicate that the brain and body may attempt to protect stored fat th

[QUIET] [HEALTH] [US]

FDA approval of Mounjaro for cardiovascular risk

2 clusters · 16 sources · last updated

Latest: FDA approves Eli Lilly's Mounjaro to reduce heart attack and stroke risk

The U.S. Food and Drug Administration (FDA) has approved Eli Lilly’s diabetes medication, Mounjaro (tirzepatide), to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who are at

[QUIET] [HEALTH] [KR]

South Korea GLP-1 obesity drug surge and illegal imports

3 clusters · 8 sources · last updated

Latest: South Korea sees 3.5x surge in illegal Wegovy and Mounjaro imports

Within ten months of their market launch in August 2023, GLP-1 obesity medicines—including Mounjaro and Wegovy—were prescribed more than 1.5 million times in South Korea. Monthly dispensing rose from under 2,000 prescrip

[QUIET] [HEALTH] [DE]

German obesity medication reimbursement debate

2 clusters · 3 sources · last updated

Latest: Germany obesity drug use rises amid health insurance cost concerns

Discussions regarding the reimbursement of GLP-1-based weight-loss medications in Germany have intensified. Sonja Optendrenk, chair of the Gemeinsamer Bundesausschuss (G-BA), suggested that statutory health insurance sho

[QUIET] [CRIME] [IN] [AE]

Regulatory enforcement against illegal weight-loss drugales

2 clusters · 3 sources · last updated

Latest: Telangana DCA raids 43 medical shops over illegal weight-loss drug sales

In Telangana, the Drugs Control Administration (DCA) conducted a statewide enforcement drive on August 14, 2026, raiding 43 medical shops. The inspections targeted the sale of prescription weight-loss medications, specif

Also covered in